Dr Donna Hogge — MD, PhD, FRCP(C)

Medical Director, Clinical Cell Therapy Lab

Research Interest
  • Medical Director, Clinical Cell Therapy Laboratory
  • Member, Leukemia Bone Marrow Transplant Program of BC
  • Clinical Professor, Medicine, University of British Columbia (UBC)
  • Member, Genetics, University of British Columbia (UBC)
  • Member, Experimental Medicine, University of British Columbia (UBC)
  • Associate Member, Pathology & Laboratory Medicine, University of British Columbia (UBC)


I retired from bench research in the Terry Fox Laboratory in 2015 and am no longer considering trainee applications.

  • Acute myeloid leukemia and myelodysplasia
  • Hematopoietic stem cell transplantation
  • Clinical cell therapy for hematologic malignancies and graft vs host disease


Acute myeloid leukemia and myelodysplasia are malignancies of the bone marrow and blood which are often fatal in spite of modern therapy.  The development of new treatments for these diseases is badly needed.  Some promising new agents which target mutations in leukemia cells are being developed and tested in patients. Through clinical research as a member of the Leukemia/Bone Marrow Transplant Program of BC I am working to bring new treatments to the clinic.

As medical director of the Clinical Cell Therapy Laboratory I oversee the processing of hematopoietic stem cell products for transplantation to cancer and leukemia patients.  In this laboratory we are also studying novel ways of using hematopoietic cells to treat complications of stem cell transplantation such as graft versus host disease and ways to optimize the use of alternative sources of hematopoietic stem cells such as umbilical cord blood for transplantation.

Selected Publications


Cortes JE, Goldberg SL, Feldman EJ, Rizzeri DA, Hogge DE, Larson M, Pigneux A, Recher C, Schiller G, Warzocha K, Kantarjian H, Louie AC & Kolitz JE. Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.  Cancer 121: 234-242, 2015. View Abstract

Yuan X, Koehn J & Hogge DE. Identification of prognostic subgroups among acute myeloid leukemia patients with intermediate risk cytogenetics using a flow-cytometry-based assessment of ABC-transporter function.  Leuk Res 39: 689-695, 2015. View Abstract 


Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC & Feldman EJ. Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60-75 years of age.  Blood 123: 3239-3246, 2014. View Abstract

Minden MD, Hogge DE, Weir SJ, Kasper J, Webster DA, Patton L, Jitkova Y, Hurren R, Gronda M, Goard CA, Rajewski LG, Haslam JL, Heppert KE, Schorno K, Chang H, Brandwein JM, Gupta V, Schuh AC, Trudel S, Yee KWL, Reed GA & Schimmer AD. Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancies.  Am J Hematol 89: 363-368, 2014. View Abstract


Xing Y & Hogge DE. Combined inhibition of the phosphoinosityl-3-kinase (PI3 kinase) P110d subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors.  Leuk Res 37: 697-704, 2013. View Abstract


Dalal BI, Mansoor S, Manna M, Pi S, Sauro GD & Hogge DE. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia.  Clin Lymphoma Myeloma Leuk 12: 274-279, 2012.  View Abstract

Kim HP, Bernard L, Berkowitz J, Nitta J & Hogge DE. Flow cytometry-based assessment of Mitoxantrone efflux from leukemic blasts varies with response to induction chemotherapy in acute myeloid leukemia.  Cytometry B Clin Cytom 82B: 283-294, 2012. View Abstract

Xing Y, Gerhard B & Hogge DE. Selective small molecule inhibitors of P110a and  d isoforms of PI3Kinase are cytotoxic to human acute myeloid leukemia progenitors .  Exp Hematol 40: 922-933, 2012. View Abstract


Cameron C, Tantiworawit A, Halpenny M, Letcher B, Berrigan S, Hindmarsh K, Giftakis A, Fortier J, O'Hoski P & Hogge D. Cryopreserved mobilized autologous blood progenitors stored for more than two years successfully support blood count recovery after high dose chemotherapy. Cytotherapy 13: 856-863, 2011. View Abstract

Kanda J, Rizzieri DA, Gasparetto C, Long GD, Chute JP, Sullivan KM, Morris A, Smith CA, Hogge DE, Nitta J, Song K, Niedzwiecki D, Chao NJ & Horwitz ME. Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350cGy) and Fludarabine conditioning.  Biol Blood Marrow Transplant 17: 867-874, 2011. View Abstract

Kim HP, Gerhard B, Harasym TO, Mayer LD & Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.  Exp Hematol 39: 741-750, 2011. View Abstract


Kim HP, Frankel AE & Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.  Leuk Res 34: 1035-1042, 2010. View Abstract

Muranyi A, Dedhar S & Hogge DE. Targeting integrin linked kinase and Fms-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors.  Leuk Res 34: 1358-1365, 2010. View Abstract


Muranyi AL, Dedhar S & Hogge DE. Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells.  Exp Hematol 37: 450-460, 2009. View Abstract


Ho MM, Hogge DE & Ling V. MDR1 and BCRP1 expression in leukemic progenitors predicts chemotherapy response in acute myeloid leukemia.  Exp Hematol 36: 433-442, 2008. View Abstract


Yalcintepe L, Frankel AE, & Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood 108 (10): 3530-7, 2006. View Abstract

Hogge DE, Yalcintepe L, Wong SH, Gerhard B, & Frankel AE. Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clin Cancer Res 12 (4): 1284-91, 2006. View Abstract


Hogge DE, Feuring-Buske M, Gerhard B, & Frankel AE. The efficacy of diphtheria-growth factor fusion proteins is enhanced by co-administration of cytosine arabinoside in an immunodeficient mouse model of human acute myeloid leukemia. Leuk Res 28 (11): 1221-6, 2004. View Abstract


Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, & Hogge DE. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17 (4): 760-3, 2003.  View Abstract

Guan Y, Gerhard B, & Hogge DE. Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML). Blood 101 (8): 3142-9, 2003. View Abstract


Guan Y, Ralph S, & Hogge DE. Polyclonal normal hematopoietic progenitors in patients with acute myeloid leukemia. Exp Hematol 30 (7): 721-8, 2002. View Abstract

Feuring-Buske M, Frankel AE, Alexander RL, Gerhard B, & Hogge DE. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Res 62 (6): 1730-6, 2002. View Abstract


Guan Y, & Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia 14 (12): 2135-41, 2000. View Abstract